← All trials
NCT05335655
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Jun 10, 2022
- Completion date
- Jun 15, 2022
- First posted
- Apr 19, 2022
- Last posted
- Jun 13, 2022
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Autonoma de San Luis PotosiLead sponsor
- Universidad Autonoma de San Luis PotosiReponsible party - principal investigator
- Universidad Autonoma de San Luis PotosiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.